Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Intense pulsed light: a novel technique to treat dry eye disease

Search Title by author or title

Session Details

Session Title: Ocular Surface & Quality of Vision

Session Date/Time: Monday 24/09/2018 | 14:00-16:00

Paper Time: 14:06

Venue: Room A3, Podium 1

First Author: : C.Rao INDIA

Co Author(s): :    S. Ganesh   S. Brar                 

Abstract Details

Purpose:

To study the efficacy of IPL (Intense Pulsed Light) for reducing signs and symptoms of evaporative dry eye disease (eDED)

Setting:

Nethradhama superspeciality eye hospital, Bangalore, India.

Methods:

In a prospective study, 24 patients with Fitzpatrick skin type III-V and evidence of eDED were treated with IPL, using the M22 OPT (Lumenis). IPL was applied to the periocular area. Each patient was treated 4 times, at 1 month intervals. Outcome measures were measured at the baseline (BL) and at 3 follow-ups (FU1, FU2, and FU3). Outcome measures included: tear break up time (TBUT), SPEED score (symptoms), Corneal fluorescein staining (CFS) (values: none, mild, moderate, or severe), and tear meniscus height (TMH). TBUT, CFS and TMH were analyzed for the eye with the lower TBUT at baseline.

Results:

Median age was 56 (range: 25 to 78). 62% of the patients were women. All tested outcome measures improved: TBUT was 4.3 +/- 1.4 sec at BL, and increased by 44%, 57%, and 84% at FU1, FU2, and FU3 respectively (p<0.01). SPEED score was 15.6 +/- 5.8 at BL, and decreased by 18% (FU1), 49% (FU2), and 43% (FU3), respectively (p<0.001). CFS was moderate at BL, and changed to mild at the 3 follow-ups (p<0.001). TMH was 0.29 +/- 0.14 mm at BL, and increased by 47% at the 3 follow-ups, but changes in TMH were not statistically significant (p=0.24).

Conclusions:

This study demonstrates that IPL is an effective tool for reducing both signs and symptoms of evaporative dry eye disease

Financial Disclosure:

-

Back to previous